Shandong Sinobioway Biomedicine Co., Ltd. (002581) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Shandong Sinobioway Biomedicine Co., Ltd.

Why is Shandong Sinobioway Biomedicine Co., Ltd. ?

Poor Management Efficiency with a low ROCE of 0%

The company has reported losses and also has negative networth. This is not a good sign for the investors. Either company will have to raise fresh capital or report profits to sustain going forward

Poor long term growth as Net Sales has grown by an annual rate of 2.14% and Operating profit at 4.90% over the last 5 years

Flat results in Mar 26

INTEREST(HY) At CNY 1.24 MM has Grown at 526.71%
OPERATING CASH FLOW(Y) Lowest at CNY -91.11 MM
NET SALES(Q) At CNY 43.86 MM has Fallen at -35.54%

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of -58.04%, its profits have fallen by -2.2%

Consistent Underperformance against the benchmark over the last 3 years

Along with generating -58.04% returns in the last 1 year, the stock has also underperformed China Shanghai Composite in each of the last 3 annual periods

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Shandong Sinobioway Biomedicine Co., Ltd. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Shandong Sinobioway Biomedicine Co., Ltd.

-100.0%

-1.47

44.06%

China Shanghai Composite

21.43%

1.73

13.79%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

2.14%

EBIT Growth (5y)

4.90%

EBIT to Interest (avg)

-31.32

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.23

Sales to Capital Employed (avg)

0.17

Tax Ratio

13.80%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

2.48%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.90

EV to EBIT

-7.27

EV to EBITDA

-8.48

EV to Capital Employed

0.89

EV to Sales

5.37

PEG Ratio

Dividend Yield

ROCE (Latest)

-12.23%

ROE (Latest)

-9.38%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Dow Theory

No Trend

Bearish

OBV

No Trend

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

20What is working for the Company

NET SALES(HY)

Higher at CNY 185.64 MM

NET PROFIT(HY)

Higher at CNY -101.7 MM

ROCE(HY)

Highest at -7.23%

INVENTORY TURNOVER RATIO(HY)

Highest at 2.99 times

-21What is not working for the Company

INTEREST(HY)

At CNY 1.24 MM has Grown at 526.71%

OPERATING CASH FLOW(Y)

Lowest at CNY -91.11 MM

NET SALES(Q)

At CNY 43.86 MM has Fallen at -35.54%

RAW MATERIAL COST(Y)

Grown by 79.22% (YoY

DEBT-EQUITY RATIO (HY)

Highest at -5.34 %

NET PROFIT(Q)

Lowest at CNY -54.23 MM

EPS(Q)

Lowest at CNY -0.24

Here's what is working for Shandong Sinobioway Biomedicine Co., Ltd.

Inventory Turnover Ratio

Highest at 2.99 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its inventory faster

Inventory Turnover Ratio

Here's what is not working for Shandong Sinobioway Biomedicine Co., Ltd.

Interest

At CNY 1.24 MM has Grown at 526.71%

over previous Semi-Annual period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (CNY MM)

Net Sales

At CNY 43.86 MM has Fallen at -35.54%

over average net sales of the previous four periods of CNY 68.04 MM

MOJO Watch

Near term sales trend is extremely negative

Net Sales (CNY MM)

Net Profit

At CNY -54.23 MM has Fallen at -86.53%

over average net sales of the previous four periods of CNY -29.07 MM

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (CNY MM)

Operating Cash Flow

Lowest at CNY -91.11 MM and Fallen

In each year in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (CNY MM)

Net Profit

Lowest at CNY -54.23 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is negative

Net Profit (CNY MM)

EPS

Lowest at CNY -0.24

in the last five periods

MOJO Watch

Declining profitability; company has created lower earnings for shareholders

EPS (CNY)

Debt-Equity Ratio

Highest at -5.34 %

in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Raw Material Cost

Grown by 79.22% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales